Dan Cocks, MD of Healthcare Equity Capital Markets, and Maneet Singh, MD of Healthcare M&A, discuss market trends and what’s driving deal making in biotech and pharma. They explore the key factors ...

This podcast series is your weekly source for differentiated perspectives, delivered in sharp, scenario-driven insights into the forces shaping tomorrow - so you can make smarter decisions today. Each ...

Despite widening cracks, from $100+ oil and renewed geopolitical tensions to higher interest rates and rising bond yields, the foundations of global growth remain intact. Strong corporate earnings, an ...

Barclays Research remains reluctantly optimistic as strong earnings, AI investment and resilient consumers support global growth despite macro headwinds.

Just as machines reshaped factories and software changed office work, humanoid robots will alter work in sectors previously untouched by automation. In the 71st edition of Barclays’ Equity Gilt Study, ...

Shareholder activists launched a record 255 campaigns in 2025, as the resurgence of M&A and equity market volatility created favourable conditions for activism. Activists reshaped corporate leadership ...

Where is healthcare innovation heading next? At our 28th Annual Global Healthcare Conference, more than 1,200 leaders, investors and experts across the healthcare ecosystem explored that very question ...

Fuelled by elevated levels in the US and record levels in APAC, global shareholder activist campaign numbers were at a six-year high in 2024. Our Investment Banking Shareholder Advisory team’s 2024 ...

Headline sentiment, driven in part by surging oil prices and private credit concerns, has turned more cautious in recent weeks, adding to market volatility. Our Research analysts acknowledge that ...

After a strong year for the hedge fund sector, what does 2025 hold? Using unique data gathered from over 300 investors representing over $8 trillion in assets, our Strategic Consulting team assesses ...

Shareholder activists launched 129 campaigns in the first half of 2025, a strong showing amid increased uncertainty, though down 12% from 2024. Our Investment Banking Shareholder Advisory team’s H1 ...